Related Parties

3 Months Ended

Mar. 31, 2019

Related Party Transactions [Abstract]

Related Parties

11. Related Parties

On October 24, 2017 the Company announced a strategic research collaboration with Mosaic Biosciences, Inc. (“Mosaic”) to develop intravitreal anti-complement factor 3 products for the treatment of dry age-related macular degeneration and other retinal diseases. According to the agreement the Company and Mosaic will co-fund the research. Dr. Usman, our Chief Executive Officer and a member of our board of directors, and Mr. Lawlor, the chairman of our board of directors, were also members of the board of directors of Mosaic when this agreement was entered in to, and the agreement was reviewed by disinterested members of our board of directors and approved by our audit committee. Expenses related to the collaboration were $0.3 and $0.2 million for the three months ended March 31, 2019 and 2018, respectively.